Needham Reiterates Buy on Cogent Biosciences, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia reiterated a Buy rating on Cogent Biosciences (NASDAQ:COGT) and maintained a $15 price target.

February 12, 2024 | 11:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterated a Buy rating on Cogent Biosciences and maintained a $15 price target.
The reiteration of a Buy rating and maintenance of a $15 price target by a reputable analyst like Ami Fadia from Needham is likely to instill confidence among investors and could lead to a positive short term impact on Cogent Biosciences' stock price. Analyst ratings, especially from well-regarded financial institutions, can significantly influence investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100